Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo

Prostate

Volumn 74, Issue 13, 2014, Pages 1251-1265

  Simmons, Jessica K ^a   Dirksen, Wessel P ^a   Hildreth, Blake E ^a   Dorr, Carlee ^b   Williams, Christina ^b   Thomas, Rachael ^b   Breen, Matthew ^b,c   Toribio, Ramiro E ^a   Rosol, Thomas J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

canine; dog; osteoblastic metastases; prostate cancer

Indexed keywords

CANINE; DOG; OSTEOBLASTIC METASTASES; PROSTATE CANCER;

ANIMALS; BONE NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOGS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOBLASTS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905925151     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22838     Document Type: Article

References (53)

1. Siegel, R. American Cancer Society Cancer facts and figures. Atlanta: American Cancer Society; 2013.
2. Chen Y, Scher HI,. Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nat Rev Clin Oncol 2012; 9 (2): 70-72.
3. Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C,. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 2013; 73 (9): 932-940.
4. Rajpar S, Fizazi K,. Bone targeted therapies in metastatic castration-resistant prostate cancer. Cancer J 2013; 19 (1): 66-70.
5. Alva A, Hussain M,. The changing natural history of metastatic prostate cancer. Cancer J 2013; 19 (1): 19-24.
6. Teske E, Naan EC, van Dijk EM, Van Garderen E, Schalken JA,. Canine prostate carcinoma: Epidemiological evidence of an increased risk in castrated dogs. Mol Cell Endocrinol 2002; 197 (1-2): 251-255.
7. Keller JM, Schade GR, Ives K, Cheng X, Rosol TJ, Piert M, Siddiqui J, Roberts WW, Keller ET,. A novel canine model for prostate cancer. Prostate 2013; 73 (9): 952-959.
8. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, Waters DJ,. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: A retrospective analysis of 76 cases. Prostate 2000; 45 (2): 173-183.
9. Sharifi N,. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 2013; 154 (11): 4010-4017.
10. Derleth CL, Yu EY,. Targeted therapy in the treatment of castration-resistant prostate cancer. Oncology (Williston Park) 2013; 27 (7): 620-628.
11. Gallardo F, Mogas T, Baro T, Rabanal R, Morote J, Abal M, Reventos J, Lloreta J,. Expression of androgen, oestrogen alpha and beta, and progesterone receptors in the canine prostate: Differences between normal, inflamed, hyperplastic and neoplastic glands. J Comp Pathol 2007; 136 (1): 1-8.
12. Leav I, Schelling KH, Adams JY, Merk FB, Alroy J,. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 2001; 48 (3): 210-224.
13. Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, Werbeck JL, Simmons JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, Rosol TJ,. Development of a brain metastatic canine prostate cancer cell line. Prostate 2011; 71 (12): 1251-1263.
14. LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, Davis D, Corn S, Rosol TJ,. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 2006; 66 (11): 1213-1222.
15. Fork MA, Murua Escobar H, Soller JT, Sterenczak KA, Willenbrock S, Winkler S, Dorsch M, Reimann-Berg N, Hedrich HJ, Bullerdiek J, Nolte I,. Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer 2008; 8: 240.
16. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O,. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001; 46 (1): 2-10.
17. Eaton CL, Pierrepoint CG,. Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: Isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1. Prostate 1988; 12 (2): 129-143.
18. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ,. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 2006; 23 (1): 19-31.
19. Breen M, Bullerdiek J, Langford CF,. The DAPI banded karyotype of the domestic dog (Canis familiaris) generated using chromosome-specific paint probes. Chromosome Res 1999; 7 (5): 401-406.
20. Thomas R, Seiser EL, Motsinger-Reif A, Borst L, Valli VE, Kelley K, Suter SE, Argyle D, Burgess K, Bell J, Lindblad-Toh K, Modiano JF, Breen M,. Refining tumor-Associated aneuploidy through "genomic recoding" of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk Lymphoma 2011; 52 (7): 1321-1335.
21. Breen M, Hitte C, Lorentzen TD, Thomas R, Cadieu E, Sabacan L, Scott A, Evanno G, Parker HG, Kirkness EF, Hudson R, Guyon R, Mahairas GG, Gelfenbeyn B, Fraser CM, Andre C, Galibert F, Ostrander EA,. An integrated 4249 marker FISH/RH map of the canine genome. BMC Genom 2004; 5 (1): 65.
22. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ III, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, DeJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, Grabherr M, Kellis M, Kleber M, Bardeleben C, Goodstadt L, Heger A, Hitte C, Kim L, Koepfli KP, Parker HG, Pollinger JP, Searle SM, Sutter NB, Thomas R, Webber C, Baldwin J, Abebe A, Abouelleil A, Aftuck L, Ait-Zahra M, Aldredge T, Allen N, An P, Anderson S, Antoine C, Arachchi H, Aslam A, Ayotte L, Bachantsang P, Barry A, Bayul T, Benamara M, Berlin A, Bessette D, Blitshteyn B, Bloom T, Blye J, Boguslavskiy L, Bonnet C, Boukhgalter B, Brown A, Cahill P, Calixte N, Camarata J, Cheshatsang Y, Chu J, Citroen M, Collymore A, Cooke P, Dawoe T, Daza R, Decktor K, DeGray S, Dhargay N, Dooley K, Dorje P, Dorjee K, Dorris L, Duffey N, Dupes A, Egbiremolen O, Elong R, Falk J, Farina A, Faro S, Ferguson D, Ferreira P, Fisher S, FitzGerald M, Foley K, Foley C, Franke A, Friedrich D, Gage D, Garber M, Gearin G, Giannoukos G, Goode T, Goyette A, Graham J, Grandbois E, Gyaltsen K, Hafez N, Hagopian D, Hagos B, Hall J, Healy C, Hegarty R, Honan T, Horn A, Houde N, Hughes L, Hunnicutt L, Husby M, Jester B, Jones C, Kamat A, Kanga B, Kells C, Khazanovich D, Kieu AC, Kisner P, Kumar M, Lance K, Landers T, Lara M, Lee W, Leger JP, Lennon N, Leuper L, LeVine S, Liu J, Liu X, Lokyitsang Y, Lokyitsang T, Lui A, Macdonald J, Major J, Marabella R, Maru K, Matthews C, McDonough S, Mehta T, Meldrim J, Melnikov A, Meneus L, Mihalev A, Mihova T, Miller K, Mittelman R, Mlenga V, Mulrain L, Munson G, Navidi A, Naylor J, Nguyen T, Nguyen N, Nguyen C, Nicol R, Norbu N, Norbu C, Novod N, Nyima T, Olandt P, O'Neill B, O'Neill K, Osman S, Oyono L, Patti C, Perrin D, Phunkhang P, Pierre F, Priest M, Rachupka A, Raghuraman S, Rameau R, Ray V, Raymond C, Rege F, Rise C, Rogers J, Rogov P, Sahalie J, Settipalli S, Sharpe T, Shea T, Sheehan M, Sherpa N, Shi J, Shih D, Sloan J, Smith C, Sparrow T, Stalker J, Stange-Thomann N, Stavropoulos S, Stone C, Stone S, Sykes S, Tchuinga P, Tenzing P, Tesfaye S, Thoulutsang D, Thoulutsang Y, Topham K, Topping I, Tsamla T, Vassiliev H, Venkataraman V, Vo A, Wangchuk T, Wangdi T, Weiand M, Wilkinson J, Wilson A, Yadav S, Yang S, Yang X, Young G, Yu Q, Zainoun J, Zembek L, Zimmer A, Lander ES,. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005; 438 (7069): 803-819.
23. Thomas R, Duke SE, Karlsson EK, Evans A, Ellis P, Lindblad-Toh K, Langford CF, Breen M,. A genome assembly-integrated dog 1 Mb BAC microarray: A cytogenetic resource for canine cancer studies and comparative genomic analysis. Cytogenet Genome Res 2008; 122 (2): 110-121.
24. Rosol TJ, Tannehill-Gregg SH, Corn S, Schneider A, McCauley LK,. Animal models of bone metastasis. Cancer Treat Res 2004; 118: 47-81.
25. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH,. Animal models of bone metastasis. Cancer 2003; 97 (3 Suppl): 748-757.
26. Schade GR, Keller J, Ives K, Cheng X, Rosol TJ, Keller E, Roberts WW,. Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. J Urol 2012; 188 (5): 1957-1964.
27. Anidjar M, Scarlata E, Cury FL, Rocha J, Hamel L, Luz M, Chevalier S,. Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men. Prostate 2012; 72 (7): 752-761.
28. Singh AS, Figg WD,. In vivo models of prostate cancer metastasis to bone. J Urol 2005; 174 (3): 820-826.
29. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET,. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107 (10): 1235-1244.
30. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL,. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002; 52 (1): 20-33.
31. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM,. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 2001; 61 (14): 5652-5659.
32. Kallioniemi A,. Bone morphogenetic protein 4-A fascinating regulator of cancer cell behavior. Cancer Genet 2012; 205 (6): 267-277.
33. Park SB, Park SH, Kim NH, Chung CK,. BMP-2 induced early bone formation in spine fusion using rat ovariectomy osteoporosis model. Spine J 2013; 13 (10): 1273-1280.
34. Chen G, Deng C, Li YP,. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8 (2): 272-288.
35. Gruber R,. Reader's digest of the pathophysiology of bone metastases. Wien Med Wochenschr 2012; 162 (17-18): 370-373.
36. Koeneman KS, Yeung F, Chung LW,. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39 (4): 246-261.
37. Rucci N, Teti A,. Osteomimicry: How tumor cells try to deceive the bone. Front Biosci 2010; 2: 907-915.
38. Gueron G, De Siervi A, Vazquez E,. Advanced prostate cancer: Reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 2012; 15 (3): 213-221.
39. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST,. Prostate-specific membrane antigen-based imaging. Urol Oncol 2013; 31 (2): 144-154.
40. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U,. Comparison of PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2013; 41 (1): 11-20.
41. Harada N, Kimura H, Ono M, Saji H,. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging. J Med Chem 2013; 56 (20): 7890-7901.
42. Franc BL, Cho SY, Rosenthal SA, Cui Y, Tsui B, Vandewalker KM, Holz AL, Poonamallee U, Pomper MG, James RB,. Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)-proof of concept and initial imaging results. Eur J Radiol 2013; 82 (11): 1877-1884.
43. Guise TA,. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2002; 2 (6): 570-572.
44. Liao J, Li X, Koh AJ, Berry JE, Thudi N, Rosol TJ, Pienta KJ, McCauley LK,. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer J Int Cancer 2008; 123 (10): 2267-2278.
45. Bryden AA, Islam S, Freemont AJ, Shanks JH, George NJ, Clarke NW,. Parathyroid hormone-related peptide: Expression in prostate cancer bone metastases. Prostate Cancer Prostatic Dis 2002; 5 (1): 59-62.
46. Liao J, McCauley LK,. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 2006; 25 (4): 559-571.
47. Smith BN, Odero-Marah VA,. The role of Snail in prostate cancer. Cell Adh Migr 2012; 6 (5): 433-441.
48. Eisenberg MC, Kim Y, Li R, Ackerman WE, Kniss DA, Friedman A,. Mechanistic modeling of the effects of myoferlin on tumor cell invasion. Proc Natl Acad Sci USA 2011; 108 (50): 20078-20083.
49. Volakis LI, Li R, Ackerman WEt, Mihai C, Bechel M, Summerfield TL, Ahn CS, Powell HM, Zielinski R, Rosol TJ, Ghadiali SN, Kniss DA,. Loss of myoferlin redirects breast cancer cell motility towards collective migration. PloS ONE 2014; 9 (2): e86110.
50. Jin G, Sun J, Liu W, Zhang Z, Chu LW, Kim ST, Sun J, Feng J, Duggan D, Carpten JD, Wiklund F, Gronberg H, Isaacs WB, Zheng SL, Xu J,. Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis 2011; 32 (7): 1057-1062.
51. Ledet EM, Hu X, Sartor O, Rayford W, Li M, Mandal D,. Characterization of germline copy number variation in high-risk African American families with prostate cancer. Prostate 2013; 73 (6): 614-623.
52. Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, Lam WL, Bristow RG,. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009; 69 (10): 1091-1100.
53. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J,. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies. Prostate 2007; 67 (7): 692-700.